A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES

吗替麦酚酯治疗先天性尿路病的初步研究

• 批准号: 7608227
• 负责人: HOWARD TRACHTMAN
• 金额: $ 0.34万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608227
• 关键词: Adult; Child; Clinical; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Inflammatory; Institution; Kidney; Kidney Diseases; Mediator of activation protein; Patients; Pilot Projects; Renal function; Research; Research Personnel; Resources; Source; Testing; Therapeutic immunosuppression; United States National Institutes of Health; design; mycophenolate mofetil; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Emerging evidence suggests that inflammatory mediators that infiltrate the kidney in children with congenital uropathies contribute to the progressive decline in kidney function that is observed in these patients. The strategy of using immunosuppressive therapy to protect against progressive, primary non-immunological forms of kidney disease has never been tested in clinical practice involving children or adult patients. This study is designed to test the hypothesis that administration of mycophenolate mofetil (MMF) to children with congenital uropathies will be safe and well tolorated and may prevent the progressive decline of kidney function in patients with congenital uropathies.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 新的证据表明，炎症介质渗入先天性尿路病儿童的肾脏，导致这些患者的肾功能逐渐下降。 使用免疫抑制治疗来预防进行性、原发性非免疫性肾脏疾病的策略从未在儿童或成年患者的临床实践中得到测试。 本研究旨在检验以下假设：给先天性尿路病儿童服用吗替麦考酚酯 (MMF) 是安全且耐受性良好的，并且可以预防先天性尿路病患者肾功能的进行性衰退。